Brain cancer drug Gleostine pulled from Medicare Part D

(By Lauren Jensik for Becker’s Hospital Review)

Brain cancer drug Gleostine is no longer available for coverage under Medicare Part D after its seller, Miami-based NextSource Biotechnology, removed it from the program, according to The Wall Street Journal.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org